Impact of ethnicity on antiplatelet treatment regimens for bleeding reduction in acute coronary syndromes: a systematic review and pre-specified subgroup meta-analysis
Pooled result · MACE, non-East Asian subgroupResult — go to the resultRelative risk 1.16 95% CI 1.09–1.24Authors' conclusion
The majority of BRATs are associated with reduced bleeding without any trade-off in hard ischaemic endpoints regardless of ethnicity. However, the supporting evidence and relative safety profiles of different BRATs might be significantly affected by ethnicity
Study context
- Population
- Patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI); East Asian and non-East Asian subgroups26 randomized controlled trials (RCTs)
- Comparison
- Bleeding reduction antiplatelet strategies (BRATs) vs standard 12-month dual antiplatelet therapy (DAPT), by ethnicity (East Asian vs non-East Asian)
- Outcome
- Efficacy: MACE as defined in each trial; safety: minor or major bleeding
Methodological detailspre-specified subgroup meta-analysis
- Pre-specified subgroup meta-analysis
Pooled result
MACE, non-East Asian subgroup
Relative risk
1.16
95% CI 1.09–1.24
Upfront unguided de-escalationvs Standard DAPT
RR 1.16 (95% CI 1.09–1.24)
As reported in the abstract
Further pooled results
Absolute risk reduction in bleeding, by ethnicity
- Some BRATs might be more effective than others in reducing bleeding according to ethnicity
Original publication
Impact of ethnicity on antiplatelet treatment regimens for bleeding reduction in acute coronary syndromes: a systematic review and pre-specified subgroup meta-analysis. Eur Heart J Cardiovasc Pharmacother. Published 13 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →